SGC's director, Aled Edwards, pens an op-ed in The Globe and Mail on stimulating innovation in Canada with open science. Full article here.
In collaboration with the SGC and the Genetic Alliance, the UNC Catalyst at the University of North Carolina will give researchers the tools and knowledge to tackle rare and orphaned diseases. The initiative was launched with a $2 million grant from the Eshelman Institute for Innovation. For the full news release, please read here.
We review this month the role(s) of bromodomains (BRDs), evolutionary conserved protein–protein interaction modules that are found in a wide range of proteins with diverse catalytic and scaffolding functions, present in most tissues. BRDs selectively recognize and bind to acetylated lysine residues, particularly acetylated histones and thereby play important roles in regulating gene expression.
Oxford, UK, December 19, 2016, Scientists from the Structural Genomics Consortium (SGC) and Oxford University report a three-dimensional view of the Polycystin-2 (PC2), a protein that causes autosomal dominant polycystic kidney disease (ADPKD) when mutated, in an article published today in Nature Structural and Molecular Biology.
Bromodomains (BRDs) have emerged as compelling targets for cancer therapy, however the complex multidomain/subunit architecture of BRD-protein complexes complicates predictions of consequences of their pharmacological targeting
Pioneering work to accelerate drug discovery earned the SGC the 2016 Oxford Academic Health Science Network (Oxford AHSN) collaboration award.
Target-enabling packages provide a crucial link between human genetics and disease biology to accelerate drug discovery in cancer and malaria
A groundbreaking partnership between the Alzheimer’s Research UK Drug Discovery Alliance (DDA) and the Structural Genomics Consortium (SGC), an international group of academic and industrial researchers with a strong track record in uncovering new drug targets and enabling new clinical trials, quickly.